This page uses content from Wikipedia and is licensed under CC BY-SA.


Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetalpha-v beta-3 integrin
Clinical data
Trade namesAbegrin
ATC code
  • none
CAS Number
  • none
Chemical and physical data
Molar mass144.3 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Etaracizumab, also known as etaratuzumab,[citation needed] MEDI-522, trade name Abegrin, is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer,[1] ovarian cancer[2] and various other types of cancer.[3] It is manufactured by MedImmune.[1]

It is an enhanced iteration of Vitaxin, also known as MEDI-523. Both are derived from the mouse antibody LM609.[4]

Adverse drug effects


  1. ^ a b Statement On A Nonproprietary Name Adopted By The Usan Council: Etaracizumab
  2. ^ Landen, CN; Kim, TJ; Lin, YG; Merritt, WM; Kamat, AA; Han, LY; Spannuth, WA; Nick, AM; Jennnings, NB (2008). "Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer". Neoplasia. 10 (11): 1259–67. doi:10.1593/neo.08740. PMC 2570602. PMID 18953435.
  3. ^ Delbaldo, C; Raymond, E; Vera, K; Hammershaimb, L; Kaucic, K; Lozahic, S; Marty, M; Faivre, S (2008). "Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors". Investigational new drugs. 26 (1): 35–43. doi:10.1007/s10637-007-9077-0. PMID 17876527.
  4. ^ McNeel, D. G. (1 November 2005). "Phase I Trial of a Monoclonal Antibody Specific for  v 3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion". Clinical Cancer Research. 11 (21): 7851–7860. doi:10.1158/1078-0432.CCR-05-0262.